Nearly a decade after PET/CT was first commercialized, vendors at RSNA 2010 took the next logical step and combined MR and PET. The result is unlike anything seen before.
Nearly a decade after PET/CT was first commercialized, vendors at RSNA 2010 took the next logical step and combined MR and PET. The result is unlike anything seen before.
Siemens Healthcare opened this year’s show with its blockbuster full-body PET/MR scanner, dubbed the Biograph mMR. A PET ring detector fitted inside a 3T magnet combine to acquire MR anatomical data and PET functional data simultaneously.
“This is the world’s first fully integrated whole-body molecular MR system,” said Walter Märzendorfer, chief executive officer of Siemens MR, “meaning that a solid-state PET camera is integrated into the isocenter of a 3T MR scanner, allowing simultaneous data acquisition of MR and PET data.”
The data are fused into images that are potentially useful in oncology, pediatric, and neuro imaging and definitely sensational to view. Head-to-toe images show MR and PET data in perfect registration in the brain, down the spine, through the abdomen, and into the extremities.
Philips Healthcare is showing off similarly remarkable results from its Ingenuity TF PET/MR.
“There is no mistaking where the lesion is,” said Dominic Smith, Philips global vice president for CT and nuclear medicine, referring to images of the breast and prostate obtained by investigators in early tests using the experimental Ingenuity TF PET/MR.
Other studies are under way using the experimental system to characterize plaques found in blood vessels, as well as to look at brain anatomy and function.
Although the clinical results are similar, Philips has taken a different design approach than Siemens. As the company did in PET/CT, it has done in this next hybridization, lining up two scanners, one for MR and the other for PET, and connecting the two with a single patient table. Data are acquired sequentially. Patients fitted with MR coils are first examined on the 3T Philips scanner, then conveyed on the patient table into the ring detector of the in-line PET scanner.
The Siemens Biograph mMR, which is prominently featured in the Siemens booth on the RSNA exhibit floor, has been installed at the University Hospital Klinikum rechts der Isar of the Munich Technical University in Germany. It is in near-production form, according to Märzendorfer. The company plans to commercialize its Biograph mMR under a CE label in the European Union in the second half of 2011. Its U.S. launch awaits successful FDA review, which Siemens is currently pursuing.
The in-line Philips system is not yet commercially available in the U.S. and will remain a work-in-progress pending FDA review, according to the company.
Meanwhile, on the RSNA exhibit floor, GE is pressing its own approach to PET/MR, one that has the advantage of being commercially available right now. Images being shown in the GE booth on the exhibit floor are constructed from data acquired during MR and PET exams performed sequentially. A patient table docks with the company’s FDA-cleared MR and PET/CT scanners. Software fuses the data sets from the two exams.
“What we want to show is that when you put these four things together (the two scanners, table, and software), you can combine the power of MR and the power of molecular imaging,” said Vivek Bhatt, GE’s general manager of PET.
Combining just the data rather than the equipment offers a financially responsible solution for the company’s customers, Bhatt said. Freestanding scanners can be used flexibly within a department, applying the PET/CT and MR pieces individually to handle routine clinical cases then using them together to conduct research.
“PET/MR is still in the research realm,” he said. “So the question is, are you going to take very expensive equipment and just have it sitting around for use once in a while when it is needed for research or would you rather have fully 510(k)-cleared systems that you can use to do reimbursable studies and generate cash flow for your site?”
It is a question that only the future can answer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
Chest CT Study Shows Higher Emphysema Risk from Combination of Marijuana and Cigarette Smoking
November 28th 2023People who smoke marijuana and cigarettes have 12 times the risk for centrilobular emphysema than non-smokers, according to new computed tomography (CT) research presented at the annual Radiological Society of North America (RSNA) conference.